Back to Newsroom

StemCells, Inc. Announces Positive Top-Line Results of Its Thoracic Spinal Cord Injury Phase I/II Study

NEWARK, Calif., May 14, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for treating diseases of the central nervous system, announced today that Dr. Armin Curt, principal investigator, will present a summary of the safety and preliminary efficacy data from the Phase I/II study investigating Human Central Nervous System Stem Cell (HuCNS-SC) intramedullary transplantation in thoracic spinal cord injury. The summary will be presented today at 10:15 a.m. EDT at the 4thJoint International Spinal Cord Society (ISCoS) and American Spinal Injury Association (ASIA) meeting being held in Montreal, Canada. The abstract was selected as one of the top six platform submissions for the conference.

Click here to read more